Anti-APOA4 Polyclonal Antibody for WB, ELISA - P06727

Core Product Specifications and Parameters

Biological Background: APOA4 Function and Localization

• APOA4, also designated Apolipoprotein A4, is a secreted protein primarily synthesized in the intestine and released into plasma.
• It serves as a major constituent of high-density lipoproteins (HDL) and chylomicrons, participating in lipid transport.
• The protein is involved in the secretion and catabolism of chylomicrons and very low-density lipoproteins (VLDL), influencing lipoprotein metabolism.
• APOA4 functions as a potent activator of lecithin-cholesterol acyltransferase (LCAT) and is required for efficient lipoprotein lipase activation by ApoC-II.
• Belonging to the apolipoprotein family with repeat regions, its molecular weight is about 45.4 kDa, and it undergoes phosphorylation as a post-translational modification.
• The protein exhibits a known 3D structure and has been implicated in amyloidosis and disease variants, making it relevant in proteomics identification studies.
• Subcellularly, APOA4 is extracellular, consistent with its secretory nature and role in circulation.

Experimental Guidance and Technical Tips

• The antibody was raised against a synthetic peptide spanning amino acids 227–396 of human APOA4. For Western blotting, denaturing sample preparation may help expose the linear epitope; consider molecular weight markers around 45 kDa.
• For ELISA applications, the immunogenic peptide can serve as a coated antigen to validate specificity, or use recombinant APOA4 protein as a standard.
• Predicted cross-reactivity with mouse and rat APOA4 indicates sequence conservation in the immunogen region; however, experimental validation in your specific sample system is recommended.
• As a polyclonal antibody, lot-to-lot consistency should be verified for critical assays, and optimal working dilutions must be determined empirically.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio offers comprehensive IVD raw material procurement, including validated antibody pairs, optimized polyclonal and monoclonal antibodies, bulk ancillary reagents, and rare-target sourcing. This APOA4 antibody supports lipid metabolism and cardiovascular disease research, and our team can assist with tailored supply solutions from concept to clinic.